Back

NanoViricides says NV-387 Ebola trial began enrollment and dosing around September 23

Verifying
  • NanoViricides began enrolling and dosing patients in an NV-387 Ebola trial.
  • Patients started receiving the oral drug around September 23.
  • The development was identified as NNVC stock news.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.